Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647471 | 0.74 | — | — | |
| SCHEMBL29361780 | 0.72 | — | — | |
| SCHEMBL41049 | 0.72 | — | — | |
| SCHEMBL2306238 | 0.72 | DPP4 (0.48) | TDP1LMNATSHRKDM4EHSP90AA1 | |
| SCHEMBL27892006 | 0.72 | LMNA (0.48) | TDP1LMNATSHRNFE2L2KDM4E | |
| SCHEMBL24500155 | 0.70 | — | — | |
| Water SCHEMBL28856304 | 0.70 | LMNA (0.46) | TDP1LMNATSHRNFE2L2KDM4E | |
| SCHEMBL8688609 | 0.70 | DPP4 (0.47) | TDP1LMNATSHRKDM4EHSP90AA1 | |
| SCHEMBL31147201 | 0.70 | — | — | |
| SCHEMBL29145897 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359401-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4353718-A1 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-17 | — | — | EP | claimed |
| WO-2022271801-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | claimed |
| US-20220396576-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | BLUEPRINT MEDICINES CORPORATION | 2022-12-15 | — | — | US | claimed |
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | claimed |
| EP-4038071-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | Blueprint Medicines Corporation (US) | 2022-08-10 | — | — | EP | claimed |
| US-20220144883-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PHOSFISH LLC | 2022-05-12 | — | — | US | claimed |
| WO-2021067670-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-04-08 | — | — | WO | claimed |
| US-20190177265-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | DOW AGROSCIENCES LLC (US) | 2019-06-13 | — | — | US | claimed |
| US-20190077744-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | DOW AGROSCIENCES LLC | 2019-03-14 | — | — | US | claimed |
| US-10125082-B2 | Method for coupling a first compound to a second compound | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-11-13 | — | — | US | claimed |
| US-20180237459-A1 | METHOD FOR COUPLING AN AROMATIC OR VINYLIC COMPOUND TO A BORON-CONTAINING COMPOUND | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-08-23 | — | — | US | claimed |
| US-20180237363-A1 | METHOD FOR COUPLING AN AROMATIC COMPOUND TO AN ALKYNE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-08-23 | — | — | US | claimed |
| US-10053426-B2 | Process for the synthesis of metyrapone and alkylated metyrapone analogs | ALBEMARLE CORPORATION (US) | 2018-08-21 | — | — | US | claimed |
| US-20170334854-A1 | One-Step Process For The Synthesis Of Alkylated Metyrapone Analogs | W. R. GRACE & CO.-CONN. | 2017-11-23 | — | — | US | claimed |
| US-20170240499-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | DOW GLOBAL TECHNOLOGIES LLC | 2017-08-24 | — | — | US | claimed |
| US-20170210695-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | DOW AGROSCIENCES LLC | 2017-07-27 | — | — | US | claimed |
| US-20170174582-A1 | METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND | DOW AGROSCIENCES LLC | 2017-06-22 | — | — | US | claimed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2009007418-A1 | NOVEL BRONCHODILATING ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237459-A1 | METHOD FOR COUPLING AN AROMATIC OR VINYLIC COMPOUND TO A BORON-CONTAINING COMPOUND | PAH, BCL6, BLVRB | SLC6A2 808/4885CASP6 398/4885TDP1 1859/4885 |
| US-20220144883-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PTMS, ACP1, SRMS | SLC6A2 4033/4885CASP6 4364/4885TDP1 1062/4885 |
| US-20190077744-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | CA6, CA2, NUDT21 | SLC6A2 576/4885CASP6 2044/4885TDP1 1609/4885 |
| US-20170174582-A1 | METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND | PAH, TYR, AHR | SLC6A2 303/4885CASP6 1599/4885TDP1 1519/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | SLC6A2 4882/4885CASP6 2066/4885TDP1 4302/4885 |
| US-20180237363-A1 | METHOD FOR COUPLING AN AROMATIC COMPOUND TO AN ALKYNE | ALK, TYR, AHR | SLC6A2 1619/4885CASP6 525/4885TDP1 1501/4885 |
| US-20190177265-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | PAICS, NUDT21, TIAL1 | SLC6A2 1724/4885CASP6 282/4885TDP1 1591/4885 |
| US-20170334854-A1 | One-Step Process For The Synthesis Of Alkylated Metyrapone Analogs | MET, MEP1B, ABL1 | SLC6A2 2864/4885CASP6 4252/4885TDP1 2997/4885 |
| US-10125082-B2 | Method for coupling a first compound to a second compound | SQLE, FDPS, PAICS | SLC6A2 3102/4885CASP6 489/4885TDP1 2659/4885 |
| US-20170210695-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | PAICS, NUDT21, TIAL1 | SLC6A2 1724/4885CASP6 282/4885TDP1 1591/4885 |
| US-10053426-B2 | Process for the synthesis of metyrapone and alkylated metyrapone analogs | MET, ABL1, CMPK1 | SLC6A2 3326/4885CASP6 3779/4885TDP1 3263/4885 |
| US-20170240499-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | SQLE, FDPS, PAICS | SLC6A2 3102/4885CASP6 489/4885TDP1 2659/4885 |
| US-20220396576-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | ACVR1, ACVRL1, BMP2K | SLC6A2 4455/4885CASP6 2728/4885TDP1 3764/4885 |
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | SLC6A2 355/4885CASP6 3712/4885TDP1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.